MYD88 and diffuse large B-cell lymphoma: In our study, five elderly DLBCL patients with MYD88<sup>mut</sup> and/or CD79B<sup>mut</sup> were achieved better ORR, CRR, PFS than the historical data of R-miniCHOP treatment and Ibrutinib + R<sup>2</sup> treatment.